References

rsp

Научно-практическая ревматология

Rheumatology Science and Practice

1995-44841995-4492

IMA-PRESS, LLC

10.47360/1995-4484-2020-520-531

rsp-2955

Research Article

ПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕ

PROGRESS IN RHEUMATOLOGY IN THE XXI CENTURY

Современная терапия интерстициальных пневмоний, ассоциированных с системной склеродермией

Current therapy of interstitial pneumonia associated with systemic scleroderma

Ананьева

Л. П.

Ananieva

L. P.

Ананьева Лидия Петровна, д.м.н., профессор, зав. лабораторией микроциркуляции и воспаления

115522, Москва, Каширское шоссе, 34а

Lidia P. Ananieva

115522, Moscow, Kashirskoe highway, 34A

lpana@yandex.ru

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2020

09112020

585520531

2020

Ананьева Л.П.

Ananieva L.P.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://rsp.mediar-press.net/rsp/article/view/2955

В последние годы был достигнут значительный прогресс в лечении тяжелых проявлений системной склеродермии (ССД), таких как феномен Рейно, почечный криз, легочная артериальная гипертензия, что привело к повышению выживаемости и качества жизни. В то же время алгоритмы лечения интерстициального поражения легких при ССД пока не разработаны. В обзоре представлена характеристика эффективности препаратов с различными механизмами действия, включая иммуносупрессивные (циклофосфамид, микофенолата мофетил и др.) и высокодозную химиотерапию с последующей трансплантацией аутологичных гемопоэтических стволовых клеток. Отдельно рассмотрены новые препараты с антифиброзной активностью, в том числе недавно зарегистрированный в России для лечения интерстициальных заболеваний легких при ССД препарат нинтеданиб, перспективы применения генно-инженерных биологических препаратов (ГИБП) (ритуксимаба, тоцилизумаба и др.), и трансплантации легких.

A significant progress has been made in recent years in management of severe systemic scleroderma (SSD) manifestations, such as Raynaud’s phenomenon, renal crisis, and pulmonary arterial hypertension, subsequently improving survival and quality of life. At the same time, treatment algorithms for interstitial lung damage in SSD have not yet been developed. The review provides relevant information on therapeutic efficacy of drugs with various mechanisms of action, including immunosuppressive drugs (cyclophosphamide, mycophenolate mofetil, etc.), and high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation. New drugs with antifibrotic activity, including recently marketed in Russia nintedanib for treatment of interstitial lung diseases in SSD, as well as perspectives for potential use of biologics (rituximab, tocilizumab, etc.), and lung transplantation are considered separately.

системная склеродермияинтерстициальные пневмониииммуносупрессантыантифиброзные препаратыритуксимабтоцилизумаб

References1

Manetti M., Matucci-Cerinic M. The new frontier in systemic sclerosis:from epigenetics to new treatments. Rheumatology. 2015;54:1757–1758. DOI: 10.1093/rheumatology/kev264.

Denton C.P., Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699. DOI: 10.1016/S0140-6736(17)30933-9

Kowal-Bielecka O., Fransen J., Avouac J., et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1133. DOI: 10.1136/annrheumdis-2016-209909. PMID: 27941129

Denton C.P., Hughes M., Gak N., et al. BSR and GHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016;55:1906–1910. DOI: 10.1093/rheumatology/kew224.

Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017:464.

Russian clinical guidelines. Rheumatology. Ed. E.L. Nasonov. Moscow: GEOTAR-Media; 2017:464 (In Russ.)

Fernández-Codina A., Walker K.M., Pope J.E., Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 2018;70:1820–182. DOI: 10.1002/art.40560.

Elhai M., Meune C., Avouac J., et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatol (Oxford). 2012;51:1017–1026. DOI: 10.1093/rheumatology/ker269.

Rubio-Rivas M., Royo C., Simeon C.P., et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Seminars in arthritis and rheumatism. 2014;44(2):208–219. DOI: 10.1016/j.semarthrit.2014.05.010.

Wijsenbeek M., Kreuter M., Amy Olson A., et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management, Current Medical Research and Opinion. 2019;35:11:2015–2024. DOI: 10.1080/03007995.2019.1647040.

Iudici M., Fasano S., Iacono D., et al. Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol. 2014;33(2):153–156. DOI: 10.1007/s10067-013-2422-0.

Adler S., Huscher D., Siegert E., et al. Systemic sclerosis associated interstitial lung disease-individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Res Ther. 2018;20(1):17. DOI: 10.1186/s13075-018-1517-z.

Hoyles R.K., Ellis R.W., Wellsbury J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–3970. DOI: 10.1002/art.22204.

Tashkin D.P., Elashoff R., Clements P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–2266. DOI: 10.1056/NEJMoa055120.

Tashkin D.P., Elashoff R., Clements P.J., et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026–1034.

Roth M.D., Tseng C.H., Clements P.J., et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum. 2011;63:2797–2808. DOI: 10.1002/art.30438.

Goldin J., Elashoff R., Kim H.J., et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009;136:1333–1340. DOI: 10.1378/chest.09-0108.

Van Den Hombergh W.M.T., Simons S.O., Teesselink E., et al. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function. Clin Rheumatol. 2018;37:2715–2722. DOI: 10.1007/s10067-018-4171-6.

Volkmann E.R., Tashkin D.P., Sim M., et al. Cyclophosphamide for Systemic Sclerosisrelated Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. J Rheumatol. 2019. [Epub ahead of print]. DOI: 10.3899/jrheum.180441.

Dan D., Fischer R., Adler S., et al. Cyclophosphamide: as bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases. Swiss Med Wkly. 2014;144:w140306. DOI: 10.4414/smw.2014.14030.

Omair M.A., Alahmadi A., Johnson S.R. Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One. 2015;10:e0124205. DOI: 10.1371/journal.pone.0124205.

Tashkin D.P., Roth M.D., Clements P.J., et al. Mycophenolate mofetil versus oral cyclophosphamide in sclerodermarelated interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–719.

Pavlov-Dolijanovic S., Vujasinovic Stupar N., Zugic V., et al. Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. Clin Rheumatol. 2018;37:30433050. DOI: 10.1007/s10067-018-4266-0.

Tyndall A., Gratwohl A.D. Adult stem cell transplantation in autoimmune disease. Curr Opin Hematol. 2009;16(4):285–291. DOI: 10.1097/MOH.0b013e32832aacb3.

Burt R.K., Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis:history and current status. Curr Opin Rheumatol. 2011;23:519–529. DOI: 10.1097/BOR.0b013e32834aa45f. PMID: 21857226

Van Laar J.M., Farge D., Sont J.K., et al. Autologous haemopoetic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490–2498. DOI: 10.1001/jama.2014.6368.

Burt R.K., Shah S.J., Dill K., et al. Autologous non-myeloablativehemotopoetic stem-cell transplantation compared with pulse cyclophosphamide once per months for systemic sclerosis (ASSIST): an open label. Randomizedphase 2 trial. Lancet. 2011;378:498–506. DOI: 10.1016/S0140-6736(11)60982-3

Sullivan K.M., Goldmuntz E.A., Keyes-Elstein L., et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35–47.

Farge D., Burt R.K., Oliveire M.C., et al. Сardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party and collaborating partners. Bone Marrow Transplantation. 2017;52:1495–1503. DOI: 10.1038/bmt.2017.56.

Del Papa N., Pignataro F., Zaccara E., et al. Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis. Front Immunol. 2018;9:2390. DOI: 10.3389/fimmu.2018.02390.

Snowden J.A., Badoglio M., Labopin M., et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. BloodAdv. 2017;1:27422755. DOI: 10.1182/bloodadvances.2017010041.

Khanna D., Tashkin D.P., Denton C.P., et al. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology. Epub ahead of print 8 June 2018. DOI: 10.1093/rheumatology/key151.

Giuggioli D., Lumetti F., Colaci M., et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev. 2015;14:1072–1078. DOI: 10.1016/j.autrev.2015.07.008.

Daoussis D., Melissaropoulos K., Sakellaropoulos G., et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. SeminArthritisRheum. 2017;46(5):625–631. DOI: 10.1016/j.semarthrit.2016.10.003.

Jordan S., Distler J.H.W., Maurer B., et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015;74:1188–1194. DOI: 10.1136/annrheumdis-2013-204522. PMID: 24442885

Sircar G., Goswami R.P., Sircar D., Ghosh A., Ghosh P. Intravenous Cyclophosphamide vs Rituximab for the Treatment of Early Diffuse Scleroderma Lung Disease: Open Label, Randomized, Controlled Trial Rheumatology (Oxford). 2018;57(12):2106–2113. DOI: 10.1093/rheumatology/key213.

Ананьева Л.П., Конева О.А., Десинова О.В. и др. Влияние ритуксимаба на проявления активности и легочную функцию у больных системной склеродермией: оценка после года наблюдения. Научно-практическая ревматология. 2019;57(3):265–273.

Ananyeva L.P., Koneva O.A., Desinova O.V. et al. The effect of rituximab on activity and pulmonary function in patients with systemic scleroderma: evaluation after a year of follow-up. Nauchno-prakticheskaya revmatologiya=Scientific and practical rheumatology. 2019;57(3):265–273 (In Russ.)

Saunders P., Tsipouri V., Keir G.J., et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18:275. DOI: 10.1186/s13063-017-2016-2.

O’Reilly S., Cant R., Ciechomska M., van Laar J.M. Interleukin-6: a newtherapeutic target in systemic sclerosis? Clin Trans Immunology. 2013;2:e4. DOI: 10.1038/cti.2013.2.

Shima Y., Kuwahara Y., Murota H., et al. The skin of patients with systemic sclerosis softened during the treatment with antiIL-6 receptor antibody tocilizumab. Rheumatology. 2010;49:2408–2412. DOI: 10.1093/rheumatology/keq275.

Elhai M., Meunier M., Matucci-Cerinic M., et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72:1217–1220. DOI: 10.1136/annrheumdis-2012-202657.

Khanna D., Denton C.P., Jahreis A., et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630–264. DOI: 10.1016/S0140-6736(16)00232-4

Khanna D., Lin C.J.F., Kuwana М., et al. Efcacy and Safety of Tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial in Proceedings of the 2018 ACR/ARHP. Annual Meeting. 2018;898.

Khanna D., Denton C.P., Lin C.J.F., et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77:212–220.

Zacay G., Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Practice & Research Clinical Rheumatology. 2018;32(4):563–571. DOI: 10.1016/j.berh.2019.01.011.

Shima Y. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. MODERN RHEUMATOLOGY. 2019;29(2):294–301. DOI: 10.1080/14397595.2018.1559909.

Fuschiotti P., Medsger T.A., Jr, Morel P.A. Effector CD8þT cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum. 2009;60(4):1119–1128. DOI: 10.1002/art.24432.

Khanna D., Spino K., Sindhu Johnson S., et al. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized. Placebo-Controlled Trial Arthritis & Rheumatology. 2020;72(1):125–136.

Sierra-Sepúlveda A., Esquinca-González A., BenavidesSuárez S.A., et al. Systemic Sclerosis Pathogenesis and Emerging Therapies. Fibroblast BioMed Research International. 2019. 15 p. DOI: 10.1155/2019/4569826.

Allanore Y., Distler О., Jagerschmidt А., et al. Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology. 2018;70(10):1634–1643. DOI: 10.1002/art.40547.

Cottin and Brown Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Research. 2019;20:13. DOI: 10.1186/s12931-019-0980-7.

Spiera R., Hummers L. Chung L. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol. 2020. DOI: 10.1002/art.41294.

Misra D.P., Ahmed S., Agarwal V. Is biological therapy in systemic sclerosis the answer? RheumatolInt. 2020;40:679–694. DOI: 10.1007/s00296-020-04515-6.

Wollin L., Maillet I., Quesniaux V., et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitornintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349:209–222. DOI: 10.1124/jpet.113.208223.

Wollin L., Wex E., Pautsch A., et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445. DOI: 10.1183/09031936.00174914.

Tandon K., Herrmann F.E., Ayaub E., et al. Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor. Am J Respir Crit Care Med. 2017;195:A2397.

Huang J., Beyer C., Palumbo-Zerr K., et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016;75:883–890. DOI: 10.1136/annrheumdis-2014-207109.

Huang J., Maier C., Zhang Y., et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76:1941–1948. DOI: 10.1136/annrheumdis-2016-210823. PMID: 28814429

Wollin L., Ostermann A., Williams C. Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease. Eur Respir J. 2017;50(Suppl. 61):PA903. DOI: 10.1183/1393003.congress-2017.PA903

Ackermann M., Kim Y.O., Wagner W.L., et al. Effects of nintedanib on the microvascular architecture in a lung f ibrosis model. Angiogenesis. 2017;20:359–372. DOI: 10.1007/s10456-017-9543-z. PMID: 28283856

Richeldi L., Du Bois R.M., Raghu G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082. DOI: 10.1056/NEJMoa1402584.

Lancaster L., Crestani B., Hernandez P., et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6:e000397. DOI: 10.1136/bmjresp-2018-000397.

Wollin L., Distler J.H.W., Denton C.P., et al. Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Disord. 2019. Epub ahead of print. DOI: 10.1177/2397198319841842

Richeldi L., Varone F., Bergna M., et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018;27(150):180074. 2018. DOI: 10.1183/16000617.0074-2018

Wells A.U., Brown K.K., Flaherty K.R., et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51:1800692. DOI: 10.1183/13993003.00692-2018.

Cottin V., Wollin L., Fischer A., Quaresma M., Stowasser S., Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100. Published 2019. DOI:10.1183/16000617.0100-2018.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, ClerismeBeaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518-2528. doi: 10.1056/NEJMoa1903076

Fischer A., Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019;38(10):2673–2681. DOI: 10.1007/s10067-019-04720-0.

Hoffmann-Vold А.-M., Weigt S.S., Saggar R., et al. Endotypephenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. E Bio Medicine 2020. DOI: 10.1016/j.ebiom.2019.10.050

Flaherty K.R., Wells A.U., Cottin V.D., et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–1727. DOI: 10.1056/NEJMoa1908681.

Clinical Trials.gov and EMD Serono Inc: National Library of Medicine (US), Abituzumab in SSc-ILD. Identifer NCT02745145. 2018. https://clinicaltrials.gov/ct2/show/NCT02745145

Clinical Trials.gov and Matucci (MD): National Library of Medicine (US), Efcacy and Safety Study of p144 to Treat Skin Fibrosis in Systemic Sclerosis. Identifer NCT00574613. 2007. clinicaltrials.gov/ct2/show/NCT00574613

Rice L.M., Padilla С.М., McLaughlin S.R., et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. Te J Clin Invest. 2015;125(7):27952807. DOI: 10.1172/JCI77958.

Khanna D. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Sclerodermaassociated Interstitial Lung Disease: the LOTUSS Trial. J. Rheumatol. 2016;43(9):1672–1679. DOI: 10.3899/jrheum.151322.

Weill D., Benden C., Corris P.A., Dark J.H., Davis R.D., Keshavjee S., et al. A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15. DOI: 10.1016/j.healun.2014.06.014.

Bernstein E.J., Peterson E.R., Sell J.L., et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheum. 2015;67(5):1314–1322. DOI: 10.1002/art.39021.

Khan I.Y., Singer L.G., de Perrot M., et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med. 2013;107(12):2081–2087. DOI: 10.1016/j.rmed.2013.09.015.

Crespo M.M., Bermudez C.A., Dew M.A., et al. Lung Transplant in Patients with Scleroderma Compared with Pulmonary Fibrosis. Short- and Long-Term Outcomes. Ann Am Thorac Soc. 2016;13(6):784–792. DOI: 10.1513/AnnalsATS.201503-177OC.

Miele C.H., Schwab K., Saggar R., et al. Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. Ann Am Thorac Soc. 2016;13(6):793–802.

Fernández-Codinaa А., Berastegui С., Pinal-Fernández I., et al. Lung transplantation in systemic sclerosis: A single center cohort study Joint Bone Spine. 2018;85(1):79–84. DOI: 10.1016/j.jbspin.2017.03.012.

Nihtyanova S.I., Tang E.C., Coghlan J.G., Wells A.U., Black С.М., Denton С.Р. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: A retrospective cohort study. QJM. 2009;103(2):109–115. DOI: 10.1093/qjmed/hcp174.

Khanna D., Distler J.H.W., Sandner P., et al. Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord. 2016;1:186–193. DOI: 10.5301/jsrd.5000207

The authors declare that there are no conflicts of interest present.